-
Innovation Ranking
NewInnovation Ranking – Intercept Pharmaceuticals Inc
Intercept Pharmaceuticals Inc (Intercept) is a biopharmaceutical company that researches, develops, and commercializes treatments for non-viral, progressive liver diseases. It develops products using proprietary bile acid chemistry. The company’s lead product candidate, obeticholic acid (OCA), is a bile acid analog and first-in-class agonist of the farnesoid X receptor. The company is advancing OCA for the treatment of various other liver diseases. The company harnesses its proprietary bile acid chemistry to develop innovative drugs. It is also advancing INT-787, an FXR...
-
Company Insights
Innovation and Patenting activity of Intercept Pharmaceuticals Inc Q4 2023
GlobalData, the industry analysis specialist, has released its latest company patent databook "Innovation and Patenting activity of Intercept Pharmaceuticals Inc Q4 2023". The databook highlights patenting activity of the company in terms of growth in filings and grants, regions protected, impact of various themes, sector applicability of technologies protected. It provides contextual analysis of technical peers, their strategy, dominance (Grant share) and their recent activities. This is an on-demand databook that will be delivered upon request. The report will be...
-
Sector Analysis
NewOman Defense Market Size, Trends, Budget Allocation, Regulations, Acquisitions, Competitive Landscape and Forecast to 2029
Oman Defense Market Report Overview The Oman defense budget is $8 billion in 2024. The country’s defense budget will grow at a CAGR of more than 2% during 2025-2029. This can be attributed to the rising arms race in the region to intercept the growing turbulence in neighboring countries such as Syria and Yemen. In addition, the increase in oil prices will facilitate increases in Oman's defense budget. Oman Defense Market Outlook, 2024-2029 ($ Billion) Buy the Full Report for...
-
Product Insights
Alcoholic Hepatitis – Drugs In Development, 2023
Global Markets Direct’s, ‘Alcoholic Hepatitis - Drugs In Development, 2023’, provides an overview of the Alcoholic Hepatitis pipeline landscape. The report provides comprehensive information on the therapeutics under development for Alcoholic Hepatitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Primary Biliary Cholangitis (Primary Biliary Cirrhosis) – Drugs In Development, 2023
Global Markets Direct’s, ‘Primary Biliary Cholangitis (Primary Biliary Cirrhosis) - Drugs In Development, 2023’, provides an overview of the Primary Biliary Cholangitis (Primary Biliary Cirrhosis) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Primary Biliary Cholangitis (Primary Biliary Cirrhosis), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development...
-
Product Insights
Liver Cirrhosis – Drugs In Development, 2023
Global Markets Direct’s, ‘Liver Cirrhosis - Drugs In Development, 2023’, provides an overview of the Liver Cirrhosis pipeline landscape. The report provides comprehensive information on the therapeutics under development for Liver Cirrhosis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Thematic Analysis
Pharma M&A Deals Q3 2023 – Top Themes – Thematic Intelligence
This report analyzes the disruptive themes that have driven M&A activity in Q3 2023 in the Pharma Sector
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – INT-787 in Alcoholic Hepatitis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - INT-787 in Alcoholic Hepatitis report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.INT-787 in Alcoholic HepatitisDrug Details:INT-787 is under development for the treatment of severe...
-
Thematic Analysis
Hypersonic Technologies – Thematic Intelligence
Hypersonic Technologies Theme Analysis Report Overview The increasing multi-polarity (and certainly the war in Ukraine) has driven intense investment by countries such as Russia, China, and the US in hypersonic technologies. These countries are all testing hypersonic technology, generating fears of escalating global competition for weaponry that has the potential to render current defenses inadequate. For instance, Russia’s use of hypersonic missiles in Ukraine has been confirmed, representing the first combat use of these weapons, and Ukraine has claimed the...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – (Bezafibrate + Obeticholic Acid) in Primary Biliary Cholangitis (Primary Biliary Cirrhosis)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - (Bezafibrate + Obeticholic Acid) in Primary Biliary Cholangitis (Primary Biliary Cirrhosis) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.(Bezafibrate + Obeticholic Acid) in Primary...